Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Liquidia Technologies Inc

LT4
Current price
9.4 EUR 0 EUR (0.00%)
Last closed 10.03 USD
ISIN US53635D2027
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 930 689 344 USD
Yield for 12 month +55.94 %
1Y
3Y
5Y
10Y
15Y
LT4
21.11.2021 - 28.11.2021

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina. Address: 419 Davis Drive, Morrisville, NC, United States, 27560

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

25.33 USD

P/E ratio

Dividend Yield

Current Year

+17 488 000 USD

Last Year

+15 935 000 USD

Current Quarter

+3 659 000 USD

Last Quarter

+2 972 000 USD

Current Year

+13 422 000 USD

Last Year

+13 076 000 USD

Current Quarter

+1 886 000 USD

Last Quarter

+1 216 000 USD

Key Figures LT4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -95 836 000 USD
Operating Margin TTM -743.29 %
PE Ratio
Return On Assets TTM -40.69 %
PEG Ratio
Return On Equity TTM -181.73 %
Wall Street Target Price 25.33 USD
Revenue TTM 14 840 000 USD
Book Value 0.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -23.5 %
Dividend Yield
Gross Profit TTM 13 076 000 USD
Earnings per share -1.58 USD
Diluted Eps TTM -1.58 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics LT4

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History LT4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation LT4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 53.9452
Price Sales TTM 62.7149
Enterprise Value EBITDA -9.4301
Price Book MRQ 14.8383

Financials LT4

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators LT4

For 52 weeks

6.1 USD 16.99 USD
50 Day MA 10.4 USD
Shares Short Prior Month 11 839 099
200 Day MA 12.43 USD
Short Ratio 11.95
Shares Short 12 132 162
Short Percent 22.16 %